Business
VYNE Therapeutics Reports Year-End 2022 Financial Results and Provides Business Update
First vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial Anticipate topline Phase 1b data in
About this update from Vyne Therapeutics Inc.
[{"type":"text","content":"First vitiligo patients being treated with pan-BD BET inhibitor, VYN201, for up to 16 weeks in Phase 1b clinical trial Anticipate topline Phase 1b data in mid-2023 BRIDGEWATER, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a clinical-stage biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the fourth quarter and year ended December 31, 2022 and provided a business update. “VYNE is making excellent progress in developing innovative therapies for the potential treatment of immuno-inflammatory conditions using our proprietary InhiBET™ platform,” said David Domzalski, President and Chief Executive Officer of VYNE. “We recently announced positive preliminary safety and tolerability data from the first part of our ongoing Phase 1a/b trial, which showed that topical administration of VYN201 produced no serious adverse events, dose adjustments or abnormal clinical laboratory results across all dose groups. These data enabled us to select three doses of VYN201 for further testing and move into a Phase 1b trial in patients with nonsegmental vitiligo.” “In addition, patient enrollment for the first dose cohort in the Phase 1b portion of the trial is complete and enrollment for the remaining two dose cohorts is ongoing,” continued Mr. Domzalski. “With only one FDA-approved therapy currently available for this large patient population, vitiligo remains a significant unmet medical need. We believe positive data from the Phase 1b trial could position VYN201 as a potential first-in-class treatment for vitiligo, while also providing the first clinical validation of our InhiBET™ BET inhibitor platform for the treatment of immuno-inflammatory disease. We look forward to providing further updates on our progress throughout the year,” concluded Mr. Domzalski. Pipeline Update VYN201 is a locally administered, small molecule, pan-bromodomain and extra-terminal domain (\"BET\") inhibitor that is being developed for the treatment of nonsegmental vitiligo. In February 2023, the Company reported positive preliminary Phase 1a safety data. Based on these preliminary results, the Company has selected three doses for testing in the Phase 1b portion of the trial....